Buhre, Wolfgang
de Korte-de Boer, Dianne
de Abreu, Marcelo Gama
Scheeren, Thomas
Gruenewald, Matthias
Hoeft, Andreas
Spahn, Donat R.
Zarbock, Alexander
Daamen, Sylvia
Westphal, Martin
Brauer, Ute
Dehnhardt, Tamara
Schmier, Sonja
Baron, Jean-Francois
De Hert, Stefan
Gavranović, Željka
Cholley, Bernard
Vymazal, Tomas
Szczeklik, Wojciech
Bornemann-Cimenti, Helmar
Soro Domingo, Marina Blanca
Grintescu, Ioana
Jankovic, Radmilo
Belda, Javier
Article History
Received: 21 September 2021
Accepted: 27 January 2022
First Online: 22 February 2022
Declarations
:
: This study was approved by Medizinische Ethikkommission der Carl von Ossietzky Universität Oldenburg, reference number 2017-008. Written, informed consent to participate will be obtained from all participants.
: Wolfgang Buhre is a member of the Steering Committee of the Prodigy Study (sponsored by Medtronic), POSE Study (supported by ESAIC), Designation Study (supported with a grant from ZonMw), and PI of the AMAZONE study (supported with grants from the Dutch Cancer Society and ESAIC). Ute Brauer, Tamara Dehnhardt, and Sonja Schmier are employees of B. Braun Melsungen AG. Martin Westphal is and Jean-Francois Baron was an employee of Fresenius Kabi. Thomas Scheeren received research grants and honoraria from Edwards Lifesciences (Irvine, CA, USA) and Masimo Inc. (Irvine, CA, USA) for consulting and lecturing and from Pulsion Medical Systems SE (Feldkirchen, Germany) for lecturing (all payments made to the institution). Matthias Grunewald has received honoraria from CSL Behring, GE Healthcare, Gruenenthal, and Vifor Pharma (all unrelated to the PHOENICS study). Donald Spahn’s department is receiving grant support from Swiss National Science Foundation, the Swiss Society of Anesthesiology and Reanimation (SGAR), the Swiss Foundation for Anesthesia Research, Vifor SA, and Vifor (International) AG, Switzerland. Dr. Spahn is co-chair of the ABC-Trauma Faculty, sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland; CSL Behring GmbH, Marburg, Germany; LFB Biomédicaments, Courtaboeuf Cedex, France; and Octapharma AG, Lachen, Switzerland. Dr. Spahn received honoraria/travel support for consulting or lecturing from Danube University of Krems, Austria; US Department of Defense, Washington, USA; European Society of Anesthesiology, Brussels, BE; Korean Society for Patient Blood Management, Seoul, Korea; Korean Society of Anesthesiologists, Seoul, Korea; Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis, Paris, France; Baxalta Switzerland AG, Volketswil, Switzerland; Bayer AG, Zürich, Switzerland; B. Braun Melsungen AG, Melsungen, Germany; Boehringer Ingelheim GmbH, Basel, Switzerland; Bristol-Myers-Squibb, Rueil-Malmaison Cedex, France and Baar, Switzerland; CSL Behring GmbH, Hattersheim am Main, Germany, and Berne, Switzerland; Celgene International II Sàrl, Couvet, Switzerland; Daiichi Sankyo AG, Thalwil, Switzerland; Haemonetics, Braintree, MA, USA; Instrumentation Laboratory (Werfen), Bedford, MA, USA; LFB Biomédicaments, Courtaboeuf Cedex, France; Merck Sharp & Dohme, Kenilworth, NJ, USA; PAION Deutschland GmbH, Aachen, Germany; Pharmacosmos A/S, Holbaek, Denmark; Pfizer AG, Zürich, Switzerland; Pierre Fabre Pharma, Alschwil, Switzerland, Portola Schweiz GmbH, Aarau, Switzerland; Roche Diagnostics International Ltd., Reinach, Switzerland; Sarstedt AG & Co., Sevelen, Switzerland and Nümbrecht, Germany; Shire Switzerland GmbH, Zug, Switzerland; Tem International GmbH, Munich, Germany; Vifor Pharma, Munich, Germany; Neuilly sur Seine, France and Villars-sur-Glâne, Switzerland; Vifor (International) AG, St. Gallen, Switzerland; and Zuellig Pharma Holdings, Singapore, Singapore. All other authors declare that they have no competing interests.